mustang
bio
announces
initial
phase
data
patients
castration
resistant
prostate
cancer
worcester
globe
newswire
mustang
bio
mustang
nasdaq
mbio
biopharmaceutical
company
focused
translating
today
medical
breakthroughs
cell
gene
therapies
potential
cures
hematologic
cancers
solid
tumors
rare
genetic
diseases
today
announced
one
patient
experience
phase
trial
prostate
stem
cell
antigen
psca
chimeric
antigen
receptor
car
administered
systemically
patients
metastatic
prostate
cancer
mcrpc
presented
virtual
annual
prostate
cancer
foundation
scientific
retreat
tanya
dorff
city
hope
associate
clinical
professor
department
medical
oncology
experimental
therapeutics
head
genitourinary
cancer
program
trial
principal
investigator
presented
description
correlative
science
ongoing
phase
clinical
trial
one
first
car
trials
prostate
cancer
nation
male
patient
mcrpc
treated
lymphodepletion
standard
car
regimen
failing
eight
prior
therapies
demonstrated
day
percent
reduction
antigen
psa
near
complete
reduction
measurable
soft
tissue
metastasis
computerized
tomography
improvement
bone
metastases
magnetic
resonance
imaging
therapy
associated
cytokine
release
syndrome
clinically
managed
tocilizumab
receptor
antibody
hemorrhagic
cystitis
requiring
transfusion
clinically
resolved
days
manuel
litchman
president
chief
executive
officer
mustang
said
encouraged
initial
data
presented
city
hope
ongoing
phase
trial
mustang
car
cell
therapy
see
potential
car
treatment
prostate
cancer
well
solid
tumor
cancers
look
forward
continued
progression
trial
anticipate
providing
data
second
half
according
american
cancer
society
acs
prostate
cancer
common
cancer
american
men
excluding
skin
cancer
acs
estimates
new
cases
prostate
cancer
diagnosed
year
roughly
one
every
nine
men
diagnosed
prostate
cancer
lifetime
median
survival
men
crpc
less
two
years
according
american
urological
association
psca
car
technology
developed
laboratory
saul
priceman
assistant
professor
city
hope
department
hematology
hematopoietic
cell
transplantation
associate
director
translational
sciences
cell
therapeutics
research
laboratory
led
stephen
forman
leader
city
hope
hematologic
malignancies
stem
cell
transplantation
institute
laboratory
director
phase
clinical
trial
continue
enroll
patients
primary
endpoints
define
safety
optimal
dosing
psca
car
cells
treating
patients
mcrpc
secondary
endpoints
include
assessing
expansion
persistence
psca
car
cells
clinical
response
based
prostate
cancer
working
group
criteria
survival
outcomes
serum
cytokine
profiles
peripheral
blood
well
describing
psca
expression
level
tumor
cells
prior
car
cell
infusion
relationship
may
disease
response
associated
toxicities
information
phase
trial
please
visit
using
identifier
mustang
bio
mustang
bio
biopharmaceutical
company
focused
translating
today
medical
breakthroughs
cell
gene
therapies
potential
cures
hematologic
cancers
solid
tumors
rare
genetic
diseases
mustang
aims
acquire
rights
technologies
licensing
otherwise
acquiring
ownership
interest
fund
research
development
outlicense
bring
technologies
market
mustang
partnered
top
medical
institutions
advance
development
car
therapies
across
multiple
cancers
well
lentiviral
gene
therapy
treatment
severe
combined
immunodeficiency
xscid
also
known
bubble
boy
disease
mustang
registered
securities
exchange
act
amended
files
periodic
reports
securities
exchange
commission
mustang
founded
fortress
biotech
nasdaq
fbio
information
visit
statements
press
release
may
contain
statements
within
meaning
section
securities
act
section
securities
exchange
act
amended
statements
include
limited
statements
relating
growth
strategy
product
development
programs
statements
historical
facts
statements
based
management
current
expectations
subject
risks
uncertainties
could
negatively
affect
business
operating
results
financial
condition
stock
value
factors
could
cause
actual
results
differ
materially
currently
anticipated
include
risks
relating
growth
strategy
ability
obtain
perform
maintain
financing
strategic
agreements
relationships
risks
relating
results
research
development
activities
risks
relating
timing
starting
completing
clinical
trials
uncertainties
relating
preclinical
clinical
testing
dependence
suppliers
ability
attract
integrate
retain
key
personnel
early
stage
products
development
need
substantial
additional
funds
government
regulation
patent
intellectual
property
matters
competition
well
risks
described
sec
filings
expressly
disclaim
obligation
undertaking
release
publicly
updates
revisions
statements
contained
herein
reflect
change
expectations
changes
events
conditions
circumstances
statement
based
except
required
law
claim
protection
safe
harbor
statements
contained
private
securities
litigation
reform
act
company
contacts
jaclyn
jaffe
william
begien
mustang
bio
ir
investor
relations
contact
daniel
ferry
lifesci
advisors
llc
daniel
media
relations
contact
tony
plohoros
degrees
tplohoros
